Impact of Probiotic Supplementation on Exercise Endurance Among Non-elite Athletes

Exercise Endurance Clinical Trial

Official title:

Impact of Probiotic Supplementation on Exercise Endurance Among Non-elite Athletes: A Randomized, Placebo-controlled, Double-blind, Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04588142
• Other study ID #: L-020
• Status: Completed
• Phase: N/A
• Start date: March 12, 2021
• Est. completion date: December 23, 2021

Study information

• Verified date: February 2023
• Source: Lallemand Health Solutions
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this trial is to evaluate the effects of 6-week administration of probiotics on running performance among non-elite athletes. It is hypothesized that participants receiving probiotics may improve their running performance at an endurance test compared to their placebo-receiving counterparts.

Description:

Participants recruited from the university community in the Southeast U.S. will participate in a randomized, double-blind, placebo-controlled interventional study for approximately 9 weeks following obtainment of informed consent. Two weeks prior to randomization participants will begin the pre-baseline period and complete daily and weekly questionnaires (physical activity and muscle soreness, bowel movements and gastrointestinal health, flu and cold symptoms). Visit 2 will occur during the pre-baseline period and participants will complete a VO2 max fitness assessment, which will be used during the endurance testing. Participants will also receive the SenseWear Armdand Mini®, a wearable device that will record their physical activity, sleeping patterns and energy expenditure for one week prior to visits 3 and 4.

Participants will be randomized at visit 3. Prior to this visit, participants will consume a standardized breakfast, collect a stool sample and a saliva sample that will be brought to site. During this visit participants will have a body composition and perform the Submaximal Treadmill Test. During the treadmill test, participants will provide finger prick samples for subsequent analysis of blood metabolites (glucose and lactate) and perceived exhaustion subjectively. Lastly, participants will complete several nutrition and motivation-related questionnaires.

One week prior to the final visit (V4), participants will be asked to wear the SenseWear Armband Mini® again for one week, which they will return at the final visit. Participants will eat another standardized breakfast prior to the final visit, visit 4. They will bring a stool and saliva sample to the site. During visit 4, participants will complete the submaximal treadmill test, while providing finger prick samples for analysis of blood and lactate levels. In addition, body composition will be assessed, as well as nutrition and motivation (subjectively). Visit 4 will be followed by a washout week, during which participants will not intake the study supplement but they will complete daily, weekly, and the final questionnaire.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: December 23, 2021
• Est. primary completion date: December 23, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Healthy adults between 18-45 years old

2. Regularly participate in running and cross-training, and willing to maintain this level of training throughout the study. Participant must satisfy all three sub-criteria:

1. 3-5 days per week of running or cross-training AND

2. 45 minutes - 1.5 hours per activity session AND

3. Run =15 miles per week

3. VO2 max values that in the 60-85th percentile (good-excellent health) range according to ACSM guidelines [1].

Exclusion Criteria:

1. Any physician-diagnosed diseases that would impact exercise performance or participation, including gastrointestinal disease, heart/cardiopulmonary disease, diabetes, thyroid disease, hypogonadism, hepatorenal disease, musculoskeletal disorder, neuromuscular/neurological disease, autoimmune disease, cancer, peptic ulcers or anemia.

2. Professional or elite athletes.

3. Use of any antibiotic drug within 4 weeks of randomization. Volunteer could be eligible to participate after a 2-week washout period.

4. Currently smoking (including vaping)

5. Pregnant, planning to get pregnant, or currently breastfeeding.

6. Lactose intolerance and/or milk, soy or yeast allergy.

Related Conditions & MeSH terms

• Exercise Endurance

Intervention

Dietary Supplement:
• Probiotic
Non-elite athletes receive probiotic for 6 weeks
• Placebo
Non-elite athletes receive placebo for 6 weeks

Locations

Country	Name	City	State
United States	UF Health Sports Performance Center	Gainesville	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Lallemand Health Solutions

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time-to exhaustion during submaximal treadmill test	Comparison of time-to exhaustion during submaximal treadmill test at the end of intervention from those that received probiotic versus placebo.	6 weeks
Secondary	Change in perceived exertion	Change from baseline in the Borg Rating of Perceived Exertion among probiotics versus placebo (score range = 9, very light effort to 20, extremely strenuous exercise)	6 weeks
Secondary	Change in blood glucose	Change from baseline in capillary blood glucose among probiotics versus placebo	6 weeks
Secondary	Change in blood lactate	Change from baseline in capillary blood lactate among probiotics versus placebo	6 weeks
Secondary	Difference in salivary stress and immune biomarkers	To compare the difference in salivary cortisol, alpha-amylase and sIgA at the end of intervention among probiotics versus placebo	6 weeks
Secondary	Difference in cold/flu episodes	To compare severity, duration and number of cold/flu episodes throughout the intervention among probiotics versus placebo, as assessed by a Visual Analogue Scale	6 weeks
Secondary	Difference in gastrointestinal function and discomfort	To compare GI function during the intervention and change in GI function from baseline among probiotics versus placebo assessed by the Gastrointestinal Symptom Rating Scale (GSRS) and the Digestion-Associated Quality of Life (DQLQ).	6 weeks
Secondary	Difference in bowel habits	To compare bowel habits during the intervention, frequency and consistency, among probiotics versus placebo assessed by the Bristol Stool Form Scale (BSFS)	6 weeks